Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Aptose Biosciences
  • Argos Therapeutics Inc.
  • Can-Fite BioPharma Ltd.
  • Celator Pharmaceuticals Inc.
  • Celldex Therapeutics Inc.
  • Cytori Therapeutics Inc.
  • DelMar Pharmaceuticals Inc.
  • Dendreon Corp.
  • Flex Pharma
  • Galena Biopharma Inc.
  • GenVec Inc.
  • Isis Pharmaceuticals Inc.
  • Lion Biotechnologies
  • MEI Pharma Inc.
  • Peregrine Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • ROTH Capital Partners
  • Stemline Therapeutics Inc.
  • Sunesis Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics Inc.
  • Verastem Inc.
  • Vericel Corp.
  • Viralytics Ltd.
  • Zosano Pharma Corp.
  • ZZ-OLD Lion Biotechnologies Inc.

Joseph Pantginis

ROTH Capital Partners

Image: Joseph Pantginis

Joseph Pantginis, Ph.D., joined ROTH Capital Partners in 2009. Prior to joining ROTH, Pantginis was a senior biotech analyst at Merriman Curhan Ford (now Merriman Holdings Inc.). Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JbHanauer & Co., First Albany Corp., Commerce Capital Markets Inc. and Ladenburg Thalmann & Co. Inc. Prior to his tenure on Wall Street, Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Pantginis received a master's degree in business administration (finance) from Pace University; a doctorate in molecular genetics and a master's degree from Albert Einstein College of Medicine; and a bachelor's degree from Fordham University.




Recent Interviews

Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15) For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here? (1/27/15) At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond. The experts also sent investors who attended the panel discussion of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist home with a bundle of robust investment opportunities, including a few new names. Read on to see which companies made the list, and why.

2015 Small-Cap Biotech Watchlist Announced (12/18/14) In its third year, The Life Sciences Report's 2015 Small-Cap Biotech Watchlist currently includes 12 drug development companies selected by leading analysts in the sector. With catalysts on the horizon and pipelines that encompass a variety of indications and innovative platforms, these biotechs are primed to return multiples on investment.

Recent Quotes

"CANF's agreement with Cipher validates the commitment to CF101." (3/23/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners Moreá>

"CANF completed development of the commercial biomarker test for A3AR." (3/18/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners Moreá>

"RNN's Phase 1 Supinoxin and RX-3117 studies wrap up around mid-2015." (3/17/15) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"We see upside for SNSS shares in 2015." (3/13/15) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"We believe 2015 will see a flurry of activity out of DMPI." (2/18/15) DelMar Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"CANF's Phase 2/3 study of CF101 in plaque psoriasis patients is complete; we believe now is a good time to buy." (2/4/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners Moreá>

"We have high confidence in CPXX's CPX-351, which meets a continuing unmet medical need." (1/20/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"SNSS shares should perform well in 2015." (12/15/14) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

more comments

"We reiterate our Buy rating for CPXX." (12/8/14) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"DMPI has a valuable, novel asset with distinguishing attributes." (11/17/14) DelMar Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"In Q3/14, SNSS reported EPS of $0.25, beating our estimate and the consensus." (11/11/14) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"The FDA gave orphan status to RNN's RX-3117 for pancreatic cancer." (9/24/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"We see significant partnering potential for CANF's rheumatoid arthritis drug." (9/2/14) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners Moreá>

"The RNN story can now be viewed as a ground floor opportunity." (8/14/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"The RNN story can now be viewed as an emerging opportunity." (7/18/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"RNN's RX-3117 has potential to be a sleeper product candidate." (6/5/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Joseph Pantginis Moreá>

"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis Moreá>

"We initiate coverage on RNN with a Buy rating." (1/9/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"Japan's new Regenerative Medicine Law is positive for CYTX." (11/21/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis Moreá>

"We are encouraged by CYTR's preliminary response data for the first-line sarcoma study." (9/30/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners Moreá>

"CYTX is a leading regenerative medicine player." (9/20/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"CYTX is poised for significant cash flow and its cardiovascular pipeline holds promise." (9/10/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

"We maintain our Buy rating on CYTR; investors should own shares." (8/6/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners Moreá>

"We believe that IMUC is well positioned to become a leading player in the cancer immunotherapy space." (7/30/13) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners Moreá>

"We reiterate our Buy rating on CYTR." (6/24/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners Moreá>

"We reinstate our Buy rating on CYTR." (5/31/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners Moreá>

"GALE is well positioned for a successful outcome of the phase 3 NeuVax PRESENT study." (5/10/13) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners Moreá>

fewer comments


Due to permission requirements, not all quotes are shown.